Preliminary injunction based on a combination product SPC is denied by Athens court

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Preliminary injunction based on a combination product SPC is denied by Athens court

Sponsored by

patrinos-logo.png
monument-2011140.jpg

Constantinos Kilimiris of Patrinos & Kilimiris calls for clarity on how to apply the SPC Regulation with regard to combination products after a Greek case appeared to overturn national case law on the matter

A recent decision by the Athens First Instance Single Member Court, hearing a request for a preliminary injunction (PI) based on a supplementary protection certificate (SPC) for a pharmaceutical product combining two active ingredients, seems to overturn national case law on the interpretation of Article 3 (c) of the SPC Regulation.

Case background and ruling

The PI application was filed by an originator company alleging infringement of its combination SPC by a generic company attempting to launch its product at risk.

The defence of the generic company was to challenge the validity of the combination SPC. The generic company alleged that:

  • The SPC was granted in violation of Article 3 (c) of the SPC Regulation as another SPC had already been granted for the first active ingredient of the marketed combination; and

  • The basic patent could not be interpreted as disclosing the active ingredients’ combination as a separate, independent invention.

While the reasoning of the decision is not very clear, it seems that the Athens court based its decision on Court of Justice of the European Union (CJEU) case law, C-443/12 and C-577/13, looking into whether the combination of active ingredients could be regarded as an independent invention of the basic patent. It ruled that this is not the case and, accordingly, that an SPC had already been granted for the same invention. Thus, the combination SPC was granted in violation of Article 3 (c) of the SPC Regulation and was invalid.

Analysis of the decision

This decision is contrary to previous case law from the same court, which, in hearing a PI application based on a combination SPC, had found that the grant of a combination SPC had not violated Article 3 (c) of the SPC Regulation as it was sufficient that the combination be expressly mentioned in the claims, without examining whether the combination could be regarded as an independent invention.

While it is true that the national case law on this issue is divergent among EU member states, it also seems that the Greek case law on this matter is far from settled. Given that referrals are pending on the same issue before the CJEU, one should hope for some clarity on how to apply the SPC Regulation in practice as regards combination products.

more from across site and SHARED ros bottom lb

More from across our site

Niri Shan, the newly appointed head of IP for UK, Ireland and the Middle East, explains why the firm’s international setup has brought UPC success, and addresses German partner departures
Vlad Stanese joins our ‘Five minutes with’ series to discuss potentially precedent-setting trademark and copyright cases and his love for aviation
Heath Hoglund, president of Via LA, discusses how it sets royalty rates and its plans to build on growth in China
Stobbs stands accused of interfering with the administration of justice after Brandsmiths’ client was subjected to an interim injunction for unjustified threats
The firm, known for its prosecution expertise, discusses its plans following the appointment of a UK-based patent litigation head and two new partners
Ed White at Clarivate provides an exclusive insight into the innovation power clusters reshaping Europe and the Middle East’s IP landscape, and why quality is the new currency of invention
In the first in a new podcast series celebrating the tenth anniversary of IP Inclusive, we look back at the network’s origins and discuss its mission
Rebecca Schwarz at Haynes Boone shares how her team secured victory for biopharma client RedHill in a licensing dispute involving a developmental cancer drug
News of a breakaway firm launching in Germany and a spike in vaccine-related patent applications were also among the top talking points
A flurry of hiring activity among UK firms suggests they are confident of mounting a serious challenge at the UPC
Gift this article